Discuss the recently published ASCO/ASTRO/SSO Guideline on the Management of Hereditary Breast Cancer and application of the practice guidelines.

The faculty for this activity are listed below:

Kandace McGuire, MD (Planner, Moderator)

Virginia Commonwealth University

Eleftherios Mamounas (Planner, Moderator, Presenter)

Orlando Health UF Health Cancer Center  

Judy Boughey, MD (Planner, Presenter)

Mayo Clinic

Anthony Dragun, MD (Planner, Presenter)

Cooper University Health Care

Jill Dietz, MD (Planner, Presenter)

Case Western Reserve School of Medicine

Ismail Jatoi, MD (Planner, Presenter)

UT Health San Antonio

Isabelle Bedrosian, MD (Planner, Presenter)

MD Anderson Cancer Center

This activity is intended for all surgeons and other health care professionals who are involved in the treatment of patients with breast cancer.

At the conclusion of this activity, participants should be able to:

• Summarize the appropriate management strategies for BRCA patients, including bilateral mastectomy, nipple sparing mastectomy and systemic therapy.
• Identify the treatment strategies for patients with ATM mutation, including bilateral mastectomy vs. MRI surveillance and nipple sparing mastectomy
• Explain the treatment strategies for patients with P53 germline mutation, including risks and benefits of radiation vs. mastectomy
• Review variants of uncertain significance (VUS) commonly seen in panel testing and how they affect treatment strategies

The Society of Surgical Oncology (SSO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Society of Surgical Oncology designates this internet enduring material for a maximum of 1 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The SSO has approved this activity for up to 1 self-assessment credit which meets the requirement of the self-assessment component of the American Board of Surgery (ABS) Continuous Certification Program.

This activity consists educational content, a self-assessment exam, and an evaluation. Learners must view the activity content, complete the self-assessment exam and achieve a minimum score of 75%. Learners will be able to review the content and repeat the self-assessment exam as many times as needed. Upon achieving a score of 75% or higher, learners will be asked to complete a post-activity evaluation. A certificate of credit or participation will be available upon successful submission of the post-activity evaluation.

The estimated time to complete this entire activity is  1 hour.

Release Date

          November 10, 2020

Expiration Date

           November 10, 2021

In accordance with the ACCME’s Accreditation Criteria, the Society of Surgical Oncology must ensure that anyone in position to control the content of this educational activity has disclosed all financial relationships with a commercial interest. All educational planners, authors, reviewers, and other individuals in a position to control or influence the content of this activity were required to disclose all financial relationships with any commercial interest that have occurred within the past 12 months. This includes the disclosure of financial relationships of a spouse or partner. The ACCME considers financial relationships to create conflicts of interest when individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest. The ACCME defines a commercial interest as “any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients.” ACCME does not consider providers of clinical service directly to patients to be commercial interests.

The ACCME also requires that the Society of Surgical Oncology resolve any reported conflict of interest and ensure the educational content of this activity is vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. If you perceive bias while participating in this activity, please advise us of the circumstances when completing your post-activity evaluation form.

All identified conflicts of interests have been resolved.

Planners, Moderators and Faculty

Kandace McGuire, MD has disclosed no financial relationships.

Eleftherios (Terry) Mamounas has disclosed the following financial relationships: Exact Sciences – Honoraria for Advisory Board, Speakers Bureau; Biotheranostics - Honoraria for Advisory Board; Daiichi Sankyo- Honoraria for Advisory Board; Puma - Honoraria for Advisory Board; Merck – Consultant; PresisCa – Consultant; Genentech/Roche - Honoraria for Advisory Board, Speakers Bureau

Judy Boughey, MD has disclosed the following financial relationship: Eli Lilly – Research grant

Anthony Dragun, MD has disclosed no financial relationships.

Jill Dietz, MD has disclosed no financial relationships.

Ismail Jatoi has disclosed no financial relationships.

Isabelle Bedrosian has disclosed no financial relationships.

Reviewers

Laura Dominici, MD has disclosed no financial relationships.

Kathie-Ann Joseph, MD has disclosed no financial relationships.

Staff

Patti Stella, CAE, CHCP, Director of Education, Society of Surgical Oncology, has disclosed the following financial relationships: Horizon Pharmaceutical PLC – Stocks; Biotech – Stocks.

The primary purpose of the Society of Surgical Oncology's enduring material is educational. Information, as well as technologies, products, and/or services, discussed are intended to inform participants about the knowledge, techniques, and experiences of specialists who are willing to share such information with colleagues. A diversity of professional opinions exists in the specialty, and the Society of Surgical Oncology disclaims any and all liability for damages to any individual using the materials and for all claims which may result from the use of information, technologies, products, and/or services discussed.

This educational activity may include discussions of unlabeled/unapproved uses of drugs or devices. Participants are advised to refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Opinions expressed in this educational activity are those of the expert contributors and do not necessarily represent the views of the Society of Surgical Oncology or any other organization associated with this activity.

For information about the Society of Surgical Oncology’s privacy policy and associated disclaimer, please visit this site: http://www.surgonc.org/disclaimer.

System requirements for this activity can be found by clicking the Help button. For technical support, please contact us at expertED@surgonc.org